{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:36Z","timestamp":1792636776274,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1836,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/s41379-018-0071-1","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T10:55:10Z","timestamp":1530010510000},"page":"1630-1644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms"],"prefix":"10.1016","volume":"31","author":[{"given":"Christina","family":"Koppel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Schwellenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Martin-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"D'Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Ulrich","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"R\u00fcschoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41379-018-0071-1_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.1038\/s41379-018-0071-1_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"key":"10.1038\/s41379-018-0071-1_bib3","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.4049\/jimmunol.1401572","article-title":"The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity","volume":"193","author":"Ostrand-Rosenberg","year":"2014","journal-title":"J Immunol"},{"key":"10.1038\/s41379-018-0071-1_bib4","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapym\u2014inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0071-1_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.oraloncology.2016.08.001","article-title":"The role of antagonists of the PD-1:PD-L1\/PD-L2 axis in head and neck cancer treatment","volume":"61","author":"Pai","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib6","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0071-1_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1038\/s41379-018-0071-1_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1038\/s41379-018-0071-1_bib9","unstructured":"Pharmaceuticals and medical devices agency. Opdivo [Review report]. 2014. http:\/\/www.pmda.go.jp\/files\/000209430.pdf. Accessed 13 Dec 2016."},{"key":"10.1038\/s41379-018-0071-1_bib10","unstructured":"Bristol-Myers Squibb. OPDIVO [prescribing information]. 2014. http:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed 8 Dec 2016."},{"key":"10.1038\/s41379-018-0071-1_bib11","unstructured":"Merck & Co. KEYTRUDA [prescribing information]. 2016. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed 8 Dec 2016."},{"key":"10.1038\/s41379-018-0071-1_bib12","unstructured":"Genentech, Inc. TECENTRIQ [prescribing information]. 2016. https:\/\/www.gene.com\/download\/pdf\/tecentriq_prescribing.pdf. Accessed 23 Jan 2017."},{"key":"10.1038\/s41379-018-0071-1_bib13","unstructured":"Bristol-Myers Squibb. OPDIVO. Summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003985\/WC500189765.pdf. Accessed 23 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib14","unstructured":"Merck & Co., Inc. KEYTRUDA. Summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003820\/WC500190990.pdf. Accessed 20 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib15","unstructured":"F Hoffmann-La Roche AG. TECENTRIQ. Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004143\/WC500235778.pdf. Accessed 3 Jan 2018."},{"key":"10.1038\/s41379-018-0071-1_bib16","unstructured":"AstraZeneca Pharmaceuticals LP. IMFINZI [prescribing information]. 2017. https:\/\/www.azpicentral.com\/imfinzi\/imfinzi.pdf#page=1. Accessed 3 Jan 2018."},{"key":"10.1038\/s41379-018-0071-1_bib17","unstructured":"Dako. PD-L1 IHC 28-8 pharmDx. 2016. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150027c.pdf. Accessed 20 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib18","unstructured":"Dako. PD-L1 IHC 28-8 pharmDx (package insert). 2017. http:\/\/www.agilent.com\/cs\/library\/packageinsert\/public\/P03914EFG_03.pdf. Accessed 10 Aug 2017."},{"key":"10.1038\/s41379-018-0071-1_bib19","unstructured":"Dako. PD-L1 IHC 28-8 pharmDx Interpretation Manual: Urothelial Carcinoma. 2017. http:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29188_pd-l1-ihc-28-8-uc-interpretation-manual.pdf. Accessed 11 Aug 2017."},{"key":"10.1038\/s41379-018-0071-1_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/030089161209800612","article-title":"Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study","volume":"98","author":"Chen","year":"2012","journal-title":"Tumori"},{"key":"10.1038\/s41379-018-0071-1_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1399-0039.2006.00701.x","article-title":"PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies","volume":"69","author":"Sun","year":"2007","journal-title":"Tissue Antigens"},{"key":"10.1038\/s41379-018-0071-1_bib23","first-page":"34","article-title":"Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer","volume":"19","author":"Sznol","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0071-1_bib24","doi-asserted-by":"crossref","first-page":"127ra137.","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/s41379-018-0071-1_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/annonc\/mdw288","article-title":"Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy","volume":"27","author":"Novotny","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/s41379-018-0071-1_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0071-1_bib28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1038\/s41379-018-0071-1_bib29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/his.13466","article-title":"Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas","volume":"72","author":"Ng Kee Kwong","year":"2018","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0071-1_bib30","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1515\/raon-2017-0037","article-title":"PD-L1 expression in squamous-cell carcinoma and adenocarcinoma of the lung","volume":"51","author":"Janzic","year":"2017","journal-title":"Radiol Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0071-1_bib32","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1038\/s41379-018-0071-1_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1038\/s41379-018-0071-1_bib34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1038\/s41379-018-0071-1_bib35","unstructured":"Edwards R, Black J, Young T, et al. Characterization of the immunomodulatory effects of nivolumab and ipilimumab in advanced melanoma by quantitative immunohistochemistry. In: 29th European Congress of Pathology: Amsterdam, Netherlands; 2017 (abstract 593)."},{"key":"10.1038\/s41379-018-0071-1_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1038\/s41379-018-0071-1_bib37","doi-asserted-by":"crossref","first-page":"e0123410","DOI":"10.1371\/journal.pone.0123410","article-title":"Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB","volume":"10","author":"Gowrishankar","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0071-1_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 antibodies to its cytoplasmic domain most clearly delineate cell membranes in immunohistochemical staining of tumor cells","volume":"3","author":"Mahoney","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/s41379-018-0071-1_bib40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/s41379-018-0071-1_bib41","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2017.35.15_suppl.3028","article-title":"Epitope mapping of PD-L1 primary antibodies (28-8, SP142, SP263, E1L3N)","volume":"35","author":"Schats","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/PAI.0000000000000605","article-title":"Development of a diagnostic programmed cell death 1-ligand 1 immunohistochemistry assay for nivolumab therapy in melanoma","volume":"26","author":"Phillips","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0071-1_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0071-1_bib44","doi-asserted-by":"crossref","first-page":"e14588","DOI":"10.1200\/JCO.2017.35.15_suppl.e14588","article-title":"Assay performance of the PD-L1 IHC 28-8 pharmDx assay in squamous cell carcinoma of the head and neck (SCCHN)","volume":"35","author":"Alvarez","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib45","doi-asserted-by":"crossref","first-page":"e14585","DOI":"10.1200\/JCO.2017.35.15_suppl.e14585","article-title":"Development of a diagnostic PD-L1 immunohistochemical assay for nivolumab therapy in urothelial carcinoma","volume":"35","author":"De Los Santos","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib47","unstructured":"Abcam. Anti-PD-L1 antibody [28-8] (ab205921). 2017. http:\/\/www.abcam.com\/pd-l1-antibody-28-8-ab205921.html. Accessed 13 Jan 2017."},{"key":"10.1038\/s41379-018-0071-1_bib48","unstructured":"Dako. Autostainer Link 48 immunohistochemistry staining system. http:\/\/www.dssimage.com\/images\/upload\/AutostainerLink48.pdf. Accessed 24 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib49","unstructured":"Dako Omnis. PD-L1 staining protocol with anti-PD-L1 clone 28-8 (Abcam) on Dako Omnis. 2015. http:\/\/www.agilent.com\/cs\/library\/datasheets\/public\/29093_dako-omnis-us-data-sheet.pdf. Accessed 14 Aug 2017."},{"key":"10.1038\/s41379-018-0071-1_bib50","unstructured":"Leica Biosystems. Leica Bond III. Fully automated IHC & ISH. 2012. https:\/\/drp8p5tqcb2p5.cloudfront.net\/fileadmin\/downloads_lbs\/Leica%20BOND-ADVANCE\/Brochures\/BOND-III_Brochure_us.pdf. Accessed 24 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib51","unstructured":"Ventana Medical Systems, Inc. BenchMark Ultra slide staining system specifications. 2013. http:\/\/www.ventana.com\/documents\/BMK_ULTRA_Spec_Sheet_web.pdf. Accessed 24 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib52","unstructured":"Horizon Discovery Group. CD274 (PD-L1) Expression IHC Reference Standard. 2017. https:\/\/www.horizondiscovery.com\/cd274-pd-l1-expression-ihc-reference-standard-hd787. Accessed 1 Mar 2017."},{"key":"10.1038\/s41379-018-0071-1_bib53","doi-asserted-by":"crossref","unstructured":"Batenchuk C, Albitar M, Sudarsanam S, et al. A comparative study of PD-L1 IHC 22C3 and 28-8 FDA-approved diagnostic assays in cancer. AACR: Washington, D.C.; 2017. (Abstract 4015).","DOI":"10.1158\/1538-7445.AM2017-4015"},{"key":"10.1038\/s41379-018-0071-1_bib54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jtho.2016.08.146","article-title":"A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana's platform","volume":"11","author":"Neuman","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40291-016-0237-9","article-title":"An analytical comparison of Dako 28-8 pharmDx assay and an E1L3N laboratory-developed test in the immunohistochemical detection of programmed death-ligand 1","volume":"21","author":"Cogswell","year":"2017","journal-title":"Mol Diagn Ther"},{"key":"10.1038\/s41379-018-0071-1_bib56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13000-016-0494-2","article-title":"Quantitative and qualitative characterization of two PD-L1 clones: SP263 and E1L3N","volume":"11","author":"Smith","year":"2016","journal-title":"Diagn Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib57","doi-asserted-by":"crossref","first-page":"e0183023","DOI":"10.1371\/journal.pone.0183023","article-title":"Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms","volume":"12","author":"Ilie","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1038\/s41379-018-0071-1_bib58","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2017.74.7642","article-title":"Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer","volume":"35","author":"Buttner","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jtho.2017.07.031","article-title":"Multicenter comparison of 22C3 pharmDx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors","volume":"12","author":"Marchetti","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/his.12996","article-title":"PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation","volume":"69","author":"Cree","year":"2016","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0071-1_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/modpathol.2017.59","article-title":"PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability","volume":"30","author":"Brunnstrom","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib62","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/modpathol.2016.213","article-title":"Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy","volume":"30","author":"Gniadek","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamaoncol.2016.3015","article-title":"A quantitative comparison of antibodies to programmed cell death 1 ligand 1","volume":"3","author":"Gaule","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/modpathol.2016.186","article-title":"Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer","volume":"30","author":"Rehman","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib65","doi-asserted-by":"crossref","first-page":"9839685","DOI":"10.1155\/2016\/9839685","article-title":"Evaluation of PD-L1 expression in tumor tissue of patients with lung carcinoma and correlation with clinical and demographic data","volume":"2016","author":"Dix Junqueira Pinto","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1038\/s41379-018-0071-1_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/PAI.0000000000000540","article-title":"Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8 pharmDx and PD-L1 IHC 22C3 pharmDx","volume":"25","author":"Skov","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/s41379-018-0071-1_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/jcp.2010.079905","article-title":"Alcohol based tissue fixation as an alternative for formaldehyde: influence on immunohistochemistry","volume":"63","author":"van Essen","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib68","unstructured":"Ventana Medical Systems, Inc. VENTANA PD-L1 (SP142) Assay [instructions for use]. 2016. http:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf16\/P160002c.pdf. Accessed 20 Feb 2017."},{"key":"10.1038\/s41379-018-0071-1_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1038\/s41379-018-0071-1_bib70","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/s41379-018-0071-1_bib71","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/his.13375","article-title":"Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer","volume":"72","author":"Scheel","year":"2018","journal-title":"Histopathology"},{"key":"10.1038\/s41379-018-0071-1_bib72","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0071-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222600024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222600024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41379-018-0071-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:56:55Z","timestamp":1760230615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222600024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0893395222600024"],"URL":"https:\/\/doi.org\/10.1038\/s41379-018-0071-1","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41379-018-0071-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}